Ulcerative Colitis Clinical Trials

Ulcerative colitis trials require documentation of continuous colonic inflammation starting from the rectum, typically confirmed by colonoscopy with specific endoscopic scoring (like the Mayo endoscopic subscore). Crohn disease trials may use different scoring systems and can involve any part of the GI tract. The diseases have distinct biology, so trial drugs and endpoints differ accordingly.

This varies by trial. Some require a washout period from biologic or immunosuppressive therapies before starting the study drug, while others allow you to continue certain background medications like aminosalicylates (mesalamine). Corticosteroid tapers are often permitted during the initial phase of a trial. Review the specific washout requirements with the trial coordinator.

Most ulcerative colitis trials enroll patients with at least moderate disease extending beyond the rectum. However, some trials specifically study topical therapies (enemas and suppositories) for left-sided disease and proctitis. If your disease is limited to the rectum, fewer trials may be available, but they do exist.

Histologic remission means that microscopic examination of colon biopsies shows resolution of inflammation at the tissue level, even beyond what appears healed on camera during colonoscopy. Research from clinical trials has shown that achieving histologic remission is associated with lower rates of flare and reduced long-term colorectal cancer risk. It is increasingly used as a trial endpoint.

Yes. A history of hospitalization for ulcerative colitis flares does not typically exclude you from trials. In fact, patients with moderate-to-severe disease who have not responded to multiple therapies are often the target population for trials testing new drugs. Your overall current health status and disease activity at screening are what matter most.